Ending the Arms Race: Ten Priorities for Fixing the Commercial Model
The drug industry has seen a massive shift in who influences prescription, payment, and consumption decisions. But corporate capabilities and tactics haven’t kept pace with these new market realities.
Faced with growing budgets and declining effectiveness of commercial spending, most large companies have embarked on the next wave of significant commercial changes. But most of these efforts don't go far enough to address the rapid and fundamental changes in the stakeholder landscape which have knocked pharma dramatically out of alignment with its stakeholder base. The article describes ten priorities for drug companies to align their organizations with these new realities - including requirements for companies to partner with payors and providers in new ways, and make resource decisions much more selectively to focus on the stakeholders who really matter. Nonetheless, these changes won't have their full effect without a more fundamental rethinking of the industry's value proposition, taking into account not only product value, but the services and the customer experience offered to all stakeholders.
You may also be interested in...
Pharmaceutical sales reps may not relish the thought, but they could play leading roles in a Hollywood epic called 'The Incredible Shrinking Sales Force.' Between 2005 and the third quarter of 2009, the number of reps industry wide in the U.S. fell from 101,818 to 81,780, a 19.7 percent decline, according to SDI Health
J&J Finds More Stakeholders Are Involved In Prescription Decisions And Thus Less Detailing Is Needed - And Eliminates 900 Pharma Sales Positions
Johnson & Johnson, like its competition, plans to respond to a changing health care environment by rolling out a new commercial model that reduces emphasis on detailing to doctors.
A selection of our favorite blog posts from March 2009 for stories not covered elsewhere in this month's IN VIVO.